I still would like to know the BS excuse that the FDA gave us after we had some early success in our secondary endpoints with mild/moderate after our phase 2 trial. We wanted to set up another one about a year ago and they told us to concentrate on severe population or something. Or that there was no market for it. Does anyone remember how they pushed us away when we were the first MAB to show success?